← Back to Clinical Trials
Recruiting NCT06240559

NCT06240559 In Vivo Treatment Verification of Brachytherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06240559
Status Recruiting
Phase
Sponsor Maastricht Radiation Oncology
Condition Brachytherapy
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-02-29
Primary Completion 2026-02

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
External imaging panel

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-02-29 with a primary completion date of 2026-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To acquire data during High Dose Rate (HDR) brachytherapy treatments aiming to track the brachytherapy source inside the patient verifying the delivery of the treatment plan. Medical images (CT,MRI and US) combined with software developed by the investigator will be employed to predict the response of the Investigational product during the treatment and will be used as reference.The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.

Eligibility Criteria

Inclusion Criteria: * Treatment site Gynaecology (Endometrium/Cervix) and prostate * Treatment: HDR Brachytherapy * Patient will be treated on CT Couch * Mentally competent patient Exclusion Criteria: * Incapacitated patient

Contact & Investigator

Central Contact

Janneke Waelen

✉ janneke.waelen@maastro.nl

📞 +31 88 445 5334

Principal Investigator

Maaike Berbée

PRINCIPAL INVESTIGATOR

Radiotherapist

Frequently Asked Questions

Who can join the NCT06240559 clinical trial?

This trial is open to participants of all sexes, studying Brachytherapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06240559 currently recruiting?

Yes, NCT06240559 is actively recruiting participants. Contact the research team at janneke.waelen@maastro.nl for enrollment information.

Where is the NCT06240559 trial being conducted?

This trial is being conducted at Maastricht, Netherlands.

Who is sponsoring the NCT06240559 clinical trial?

NCT06240559 is sponsored by Maastricht Radiation Oncology. The principal investigator is Maaike Berbée at Radiotherapist. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology